Table 1.
Expression of VEGFs and VEGF receptors in human cancers*
| VEGF or receptor | Cancer |
|---|---|
| VEGFs | |
| VEGF | Bladder129,130, brain14,131,132, breast‡ (REFS 38,133–135), colon‡ (REFS 87,136), gastric‡ (REF. 137), oral squamous‡ (REFS 138,139), lung‡ (REFS 140–143), mesothelioma‡ (REF. 144), myeloid leukaemia145, ovarian146,147, pancreatic91,148 and prostate§ (REFS 149–151) |
| VEGFB | Breast|| (REFS 134,152) and lung140 |
| VEGFC | Breast153, cervical|| (REFS 153–155), colon‡|| (REFS 153,156,157), gastric158, oral squamous159, lung‡ (REFS 140,153,160) and prostate153 |
| VEGFD | Cervical154, gastric161 and lung140 |
| PLGF | Breast¶ (REF. 162), colon‡ (REF. 136), gastric‡§|| (REF. 163) and hepatocellular¶ (REF. 164) |
| VEGF receptors | |
| VEGFR1 | Bladder130, brain131,132, breast‡ (REFS 133–135,152,165), colon18,92, head and neck166, lung‡ (REFS 140–142), melanoma167, mesothelioma144, myeloid leukaemia145, oesophageal168, ovarian86,146,147, pancreatic (REFS 91,148) and prostate (REF. 169) |
| VEGFR2 | Bladder§ (REF. 129), brain14,131,132,161,170,171, breast‡ (REFS 133,135,172), cervical173, colon§|| (REFS 87,174), endometrial‡ (REF. 175), gastric137, head and neck166,176, hepatocellular‡ (REF. 177), lung‡ (REFS 140–142,178), melanoma167, mesothelioma144, multiple myeloma179, myeloid leukaemia145, oesophageal168, ovarian86,146,147, pancreatic91,148, prostate149,169, renal cell carcinoma180, squamous181 and thyroid|| (REF. 182) |
| VEGFR3 | Breast153, cervical§ (REFS 153,154), colon‡|| (REFS 153,156), gastric‡|| (REFS 158,161), head and neck159,166, lung‡§ (REFS 140,153,160), oesophageal168 and prostate153 |
| NRP1 | Brain|| (REFS 14,63,183,184), breast‡ (REFS 135,185,186), colon§ (REFS 83,187,188), lung143,185,189, melanoma167, ovarian147,190,191, pancreatic84,188,192–194 and prostate§¶ (REFS 150,151,195) |
| NRP2 | Bladder196, breast38,186,197,198, colon113,197, lung143,189,197, melanoma197,199, ovarian190, pancreatic193,194, prostate‡§ (REF. 15) and renal cell§|| (REF. 200) |
NRP, neuropilin; PLGF, placental growth factor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.
*
The data reported are primarily based on immunohistochemical analyses of tumours and indicate expression of VEGFs or VEGF receptors specifically in tumour cells.
‡
Studies that showed a correlation between expression and poor survival or outcome.
§
Studies that showed a correlation between expression and disease stage or progression.
||
Studies that showed a correlation between expression and metastasis.
¶
Studies that showed a correlation between expression and recurrence.